updated 5/17/2011 8:46:42 AM ET 2011-05-17T12:46:42

DELRAY BEACH, Fla., May 17, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has filed a utility patent application with the U.S. Patent and Trademark Office covering a passive radio frequency ("RF") powered electromechanical sensor for the continuous detection of glucose levels in a patient. This application represents the ongoing advancements the Company has made from its provisional filing last year. The technology represented by this utility patent is being utilized in the Company's development of its GlucoChip™ glucose-sensing microchip, and could also be employed in the technologies developed by MicroFluidic Systems, a leader in biological testing and sample preparation applications, a company which PositiveID announced earlier this week it has agreed to acquire.

This new system integrates RF technology, such as that described in PositiveID's previously issued Patent No. 7,125,382 entitled "Embedded Bio-Sensor System," to power and communicate remotely with an implanted sensor. One or more microelectromechanical system (MEMS) devices inside the sensor register physical changes reflecting glucose levels in vivo, which are communicated via integrated electronics to an external reader. 

Surface chemistries for glucose binding to the MEMS devices have been developed by the Company in conjunction with partner RECEPTORS LLC, and are exclusively licensed to PositiveID for this application. Advanced technologies for MEMS device fabrication and surface treatment are also exploited for high sensitivity.

The wireless molecular sensor described in the patent application is battery-free and designed for extended use. It represents an alternative to frequent finger pricks or other painful and/or harmful glucose monitoring methods for certain diabetic patients.

Scott R. Silverman, Chairman and CEO of PositiveID, said:  "This filing marks another step in the progress we continue to make in the development of our glucose-sensing microchip and expansion of our IP portfolio.  This small, implantable sensor technology also complements other technologies in the Company, including the recent acquisition of MicroFluidic Systems and its molecular diagnostics platforms. We believe there are synergies between these micro-technologies and micro-analytics to improve both in vitro and in vivo tests."

About PositiveID Corporation

PositiveID Corporation develops and markets healthcare and information management products through its RFID-based diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID operates in two main divisions: HealthID and ID Security. For more information on PositiveID, please visit www.PositiveIDCorp.com .

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the likelihood that the U.S. Patent and Trademark Office will grant a patent based on the patent application filing, the Company's ability to successfully develop, fund and commercialize an implantable glucose sensing microchip, the likelihood that this patent application that can also be utilized with MicroFluidic Systems' biological testing technologies, the likelihood that PositiveID will complete its acquisition of MicroFluidic Systems, the ability of the wireless molecular sensor described in the patent application represents an alternative to frequent finger pricks or other painful and/or harmful glucose monitoring methods for certain diabetic patients, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully develop, fund and commercialize an implantable glucose sensing microchip, its ability to complete its acquisition of MicroFluidic Systems, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Q filed on May 13, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Allison Tomek
         561-805-8000
         atomek@positiveidcorp.com
         
         Dan Schustack
         CEOcast
         212-732-4300
         dschustack@ceocast.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com